Have you been paying attention to shares of Baxter International (BAX - Free Report) ? Shares have been on the move with the stock up 6% over the past month. The stock hit a new 52-week high of $78.46 in the previous session. Baxter International has gained 19.2% since the start of the year compared to the 10.4% move for the Zacks Medical sector and the 14.3% return for the Zacks Medical - Products industry.
What's Driving the Outperformance?
The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on January 31, 2019, Baxter reported EPS of $0.78 versus consensus estimate of $0.73 while it beat the consensus revenue estimate by 1.45%.
For the current fiscal year, Baxter is expected to post earnings of $3.27 per share on $11.22 billion in revenues. This represents a 7.21% change in EPS on a 0.83% change in revenues. For the next fiscal year, the company is expected to earn $3.7 per share on $11.76 billion in revenues. This represents a year-over-year change of 13.09% and 4.8%, respectively.
Baxter may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level.
On this front, we can look at the Zacks Style Scores, as these give investors a variety of ways to comb through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style.
Baxter has a Value Score of C. The stock's Growth and Momentum Scores are B and C, respectively, giving the company a VGM Score of B.
In terms of its value breakdown, the stock currently trades at 24X current fiscal year EPS estimates. On a trailing cash flow basis, the stock currently trades at 17X versus its peer group's average of 18.2X. Additionally, the stock has a PEG ratio of 1.97. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.
We also need to look at the Zacks Rank for the stock, as this supersedes any trend on the style score front. Fortunately, Baxter currently has a Zacks Rank of #2 (Buy) thanks to favorable earnings estimate revisions from covering analysts.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Baxter passes the test. Thus, it seems as though Baxter shares could have potential in the weeks and months to come.
How Does Baxter Stack Up to the Competition?
Shares of Baxter have been rising, and the company still appears to be a decent choice, but what about the rest of the industry? Some of its industry peers are also impressive, including Abbott Laboratories (ABT - Free Report) , Stryker (SYK - Free Report) , and ICU Medical (ICUI - Free Report) , all of which currently have a Zacks Rank of at least #2 and a VGM Score of at least B, making them well-rounded choices.
The Zacks Industry Rank is in the top 35% of all the industries we have in our universe, so it looks like there are some nice tailwinds for Baxter, even beyond its own solid fundamental situation.